Frank Scott
Concepts (325)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Inflammatory Bowel Diseases | 28 | 2026 | 360 | 8.490 |
Why?
| | Crohn Disease | 16 | 2025 | 256 | 5.530 |
Why?
| | Gastrointestinal Agents | 7 | 2025 | 67 | 3.370 |
Why?
| | Gastroenterology | 7 | 2025 | 186 | 2.120 |
Why?
| | Colitis, Ulcerative | 9 | 2025 | 145 | 2.070 |
Why?
| | Infliximab | 10 | 2022 | 111 | 1.540 |
Why?
| | Intestinal Obstruction | 3 | 2021 | 53 | 1.470 |
Why?
| | Tissue Adhesions | 3 | 2021 | 33 | 1.250 |
Why?
| | Immunosuppressive Agents | 6 | 2020 | 859 | 1.250 |
Why?
| | Adrenal Cortex Hormones | 4 | 2022 | 502 | 1.120 |
Why?
| | Tumor Necrosis Factor-alpha | 10 | 2023 | 1225 | 1.110 |
Why?
| | Antibodies, Monoclonal, Humanized | 5 | 2025 | 917 | 1.080 |
Why?
| | Algorithms | 7 | 2026 | 1791 | 1.010 |
Why?
| | Intestine, Small | 2 | 2021 | 158 | 0.960 |
Why?
| | Patient Acceptance of Health Care | 5 | 2026 | 879 | 0.950 |
Why?
| | Biological Products | 4 | 2026 | 243 | 0.930 |
Why?
| | Ustekinumab | 2 | 2025 | 18 | 0.890 |
Why?
| | JC Virus | 2 | 2015 | 23 | 0.870 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 2 | 2015 | 38 | 0.860 |
Why?
| | Azathioprine | 5 | 2021 | 51 | 0.800 |
Why?
| | Bone Diseases, Metabolic | 1 | 2023 | 64 | 0.790 |
Why?
| | Humans | 91 | 2026 | 142526 | 0.790 |
Why?
| | Abdominal Abscess | 1 | 2022 | 25 | 0.750 |
Why?
| | Abdomen | 2 | 2021 | 140 | 0.740 |
Why?
| | Esophageal Neoplasms | 6 | 2022 | 343 | 0.730 |
Why?
| | Drug Monitoring | 1 | 2026 | 396 | 0.730 |
Why?
| | Gastrointestinal Hemorrhage | 3 | 2023 | 135 | 0.680 |
Why?
| | Postoperative Complications | 3 | 2021 | 2862 | 0.670 |
Why?
| | Severity of Illness Index | 9 | 2025 | 2927 | 0.660 |
Why?
| | Retrospective Studies | 27 | 2026 | 16626 | 0.660 |
Why?
| | Splints | 1 | 2020 | 15 | 0.660 |
Why?
| | Capsule Endoscopy | 1 | 2020 | 18 | 0.650 |
Why?
| | Anti-Bacterial Agents | 5 | 2018 | 1881 | 0.650 |
Why?
| | Antibodies, Viral | 2 | 2015 | 664 | 0.640 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2020 | 27 | 0.630 |
Why?
| | Biomedical Research | 2 | 2019 | 692 | 0.610 |
Why?
| | Barrett Esophagus | 4 | 2023 | 166 | 0.610 |
Why?
| | Radius Fractures | 1 | 2020 | 67 | 0.610 |
Why?
| | Quality-Adjusted Life Years | 5 | 2021 | 112 | 0.590 |
Why?
| | Spondylarthritis | 3 | 2025 | 50 | 0.580 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2021 | 449 | 0.580 |
Why?
| | Colonoscopy | 7 | 2024 | 251 | 0.570 |
Why?
| | Hospitalization | 4 | 2026 | 2293 | 0.560 |
Why?
| | Drug Utilization | 1 | 2019 | 166 | 0.560 |
Why?
| | Adult | 37 | 2026 | 39715 | 0.560 |
Why?
| | Intestinal Fistula | 1 | 2018 | 17 | 0.560 |
Why?
| | Colonic Diseases | 1 | 2018 | 36 | 0.550 |
Why?
| | Health Resources | 1 | 2019 | 129 | 0.550 |
Why?
| | Tuberculin Test | 1 | 2017 | 36 | 0.550 |
Why?
| | Surgical Procedures, Operative | 1 | 2021 | 273 | 0.540 |
Why?
| | Pericardium | 1 | 2018 | 60 | 0.540 |
Why?
| | Cost-Benefit Analysis | 5 | 2021 | 618 | 0.540 |
Why?
| | Biological Factors | 2 | 2023 | 39 | 0.530 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2018 | 100 | 0.520 |
Why?
| | Models, Statistical | 2 | 2019 | 677 | 0.520 |
Why?
| | Latent Tuberculosis | 1 | 2017 | 70 | 0.510 |
Why?
| | Male | 48 | 2026 | 70910 | 0.510 |
Why?
| | Middle Aged | 37 | 2026 | 35049 | 0.500 |
Why?
| | Time-to-Treatment | 2 | 2019 | 227 | 0.500 |
Why?
| | Mass Screening | 4 | 2021 | 1325 | 0.500 |
Why?
| | Colorectal Neoplasms | 6 | 2024 | 824 | 0.480 |
Why?
| | Remission Induction | 3 | 2025 | 306 | 0.480 |
Why?
| | Treatment Outcome | 14 | 2025 | 11298 | 0.480 |
Why?
| | Antibodies, Monoclonal | 4 | 2021 | 1471 | 0.470 |
Why?
| | Natalizumab | 1 | 2015 | 40 | 0.450 |
Why?
| | Radius | 1 | 2015 | 52 | 0.450 |
Why?
| | Heart Diseases | 1 | 2018 | 339 | 0.430 |
Why?
| | Fracture Fixation | 1 | 2015 | 84 | 0.430 |
Why?
| | Mycobacterium tuberculosis | 1 | 2017 | 327 | 0.420 |
Why?
| | Models, Theoretical | 1 | 2018 | 585 | 0.420 |
Why?
| | Age Factors | 5 | 2025 | 3316 | 0.420 |
Why?
| | Female | 44 | 2026 | 76624 | 0.410 |
Why?
| | Practice Patterns, Physicians' | 3 | 2024 | 1353 | 0.400 |
Why?
| | Leukocyte L1 Antigen Complex | 2 | 2026 | 39 | 0.400 |
Why?
| | Aged | 27 | 2024 | 25117 | 0.400 |
Why?
| | Markov Chains | 3 | 2020 | 126 | 0.390 |
Why?
| | Lymphoma | 1 | 2014 | 228 | 0.380 |
Why?
| | Risk Factors | 17 | 2025 | 10593 | 0.380 |
Why?
| | Drug Therapy, Combination | 4 | 2024 | 1053 | 0.370 |
Why?
| | Adalimumab | 3 | 2021 | 55 | 0.370 |
Why?
| | Communicable Diseases | 1 | 2014 | 165 | 0.360 |
Why?
| | Patient Discharge | 2 | 2023 | 920 | 0.360 |
Why?
| | Feces | 3 | 2026 | 494 | 0.350 |
Why?
| | United Kingdom | 5 | 2021 | 325 | 0.350 |
Why?
| | Gastroenterologists | 2 | 2022 | 17 | 0.350 |
Why?
| | Professional Competence | 1 | 2012 | 96 | 0.350 |
Why?
| | Disease Management | 3 | 2021 | 641 | 0.340 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2016 | 643 | 0.330 |
Why?
| | Cohort Studies | 10 | 2025 | 5858 | 0.330 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 351 | 0.330 |
Why?
| | Research Design | 2 | 2019 | 1113 | 0.330 |
Why?
| | Spondylitis, Ankylosing | 2 | 2021 | 47 | 0.330 |
Why?
| | Research Personnel | 1 | 2012 | 177 | 0.320 |
Why?
| | Fractures, Bone | 1 | 2015 | 409 | 0.320 |
Why?
| | Gastroesophageal Reflux | 2 | 2023 | 244 | 0.320 |
Why?
| | Adenoma | 3 | 2024 | 218 | 0.320 |
Why?
| | Colonic Polyps | 2 | 2024 | 82 | 0.320 |
Why?
| | United States | 17 | 2025 | 15447 | 0.300 |
Why?
| | Proportional Hazards Models | 5 | 2021 | 1284 | 0.300 |
Why?
| | Urinary Bladder Neoplasms | 3 | 2017 | 258 | 0.290 |
Why?
| | Pediatric Obesity | 1 | 2016 | 617 | 0.290 |
Why?
| | Janus Kinase Inhibitors | 2 | 2025 | 27 | 0.290 |
Why?
| | Societies, Medical | 4 | 2025 | 866 | 0.280 |
Why?
| | Skin Neoplasms | 1 | 2016 | 856 | 0.280 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2025 | 1642 | 0.270 |
Why?
| | Incidence | 8 | 2021 | 2826 | 0.270 |
Why?
| | Quality of Life | 2 | 2021 | 3064 | 0.270 |
Why?
| | Electronic Health Records | 6 | 2022 | 1144 | 0.260 |
Why?
| | Mortality | 2 | 2020 | 362 | 0.250 |
Why?
| | Databases, Factual | 7 | 2018 | 1458 | 0.250 |
Why?
| | Consensus | 2 | 2025 | 546 | 0.240 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2017 | 1087 | 0.240 |
Why?
| | Maintenance Chemotherapy | 1 | 2025 | 38 | 0.240 |
Why?
| | Radiography | 2 | 2020 | 846 | 0.230 |
Why?
| | Adenocarcinoma | 3 | 2022 | 904 | 0.230 |
Why?
| | Population Surveillance | 2 | 2021 | 485 | 0.230 |
Why?
| | Referral and Consultation | 2 | 2023 | 822 | 0.230 |
Why?
| | Induction Chemotherapy | 1 | 2025 | 84 | 0.230 |
Why?
| | Antifungal Agents | 2 | 2016 | 147 | 0.220 |
Why?
| | Aged, 80 and over | 10 | 2020 | 8020 | 0.220 |
Why?
| | Evidence-Based Medicine | 2 | 2025 | 721 | 0.220 |
Why?
| | Case-Control Studies | 8 | 2021 | 3604 | 0.220 |
Why?
| | Recurrence | 5 | 2021 | 1111 | 0.210 |
Why?
| | Delivery of Health Care | 2 | 2021 | 952 | 0.210 |
Why?
| | Esophageal Stenosis | 2 | 2014 | 56 | 0.210 |
Why?
| | Surveys and Questionnaires | 8 | 2025 | 5994 | 0.200 |
Why?
| | C-Reactive Protein | 1 | 2026 | 417 | 0.200 |
Why?
| | Gastrointestinal Microbiome | 2 | 2022 | 727 | 0.200 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2024 | 92 | 0.200 |
Why?
| | Obesity | 1 | 2017 | 3027 | 0.200 |
Why?
| | Protective Factors | 2 | 2021 | 96 | 0.200 |
Why?
| | Esophagitis, Peptic | 1 | 2023 | 17 | 0.200 |
Why?
| | Colectomy | 2 | 2021 | 107 | 0.200 |
Why?
| | Models, Economic | 2 | 2020 | 61 | 0.190 |
Why?
| | Glucocorticoids | 2 | 2018 | 535 | 0.190 |
Why?
| | Logistic Models | 6 | 2018 | 2102 | 0.190 |
Why?
| | Absorptiometry, Photon | 1 | 2023 | 268 | 0.190 |
Why?
| | Prognosis | 4 | 2019 | 4112 | 0.190 |
Why?
| | Comparative Effectiveness Research | 2 | 2024 | 164 | 0.180 |
Why?
| | Cellulitis | 1 | 2022 | 55 | 0.180 |
Why?
| | Medical Marijuana | 1 | 2024 | 124 | 0.180 |
Why?
| | Odds Ratio | 4 | 2018 | 1057 | 0.180 |
Why?
| | Insurance, Health | 1 | 2024 | 299 | 0.180 |
Why?
| | Amputation, Traumatic | 1 | 2021 | 21 | 0.170 |
Why?
| | Necrosis | 1 | 2022 | 246 | 0.170 |
Why?
| | Finger Injuries | 1 | 2021 | 26 | 0.170 |
Why?
| | Rectal Fistula | 1 | 2021 | 27 | 0.170 |
Why?
| | Liver Transplantation | 2 | 2021 | 811 | 0.170 |
Why?
| | Aftercare | 1 | 2023 | 218 | 0.170 |
Why?
| | Pancreatic Neoplasms | 2 | 2021 | 895 | 0.170 |
Why?
| | Vascular Surgical Procedures | 2 | 2021 | 341 | 0.170 |
Why?
| | Prevalence | 4 | 2025 | 2817 | 0.170 |
Why?
| | Follow-Up Studies | 4 | 2021 | 5270 | 0.170 |
Why?
| | Gynecologic Surgical Procedures | 1 | 2021 | 66 | 0.160 |
Why?
| | Cystectomy | 2 | 2017 | 42 | 0.160 |
Why?
| | Utilization Review | 1 | 2020 | 41 | 0.160 |
Why?
| | Esophagoscopy | 2 | 2022 | 219 | 0.160 |
Why?
| | Sugars | 1 | 2020 | 42 | 0.160 |
Why?
| | Practice Guidelines as Topic | 2 | 2025 | 1552 | 0.160 |
Why?
| | Digestive System Surgical Procedures | 1 | 2021 | 109 | 0.160 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2020 | 37 | 0.160 |
Why?
| | Carcinoma | 1 | 2021 | 230 | 0.160 |
Why?
| | Bone Plates | 1 | 2020 | 79 | 0.160 |
Why?
| | Bone Density | 1 | 2023 | 499 | 0.150 |
Why?
| | Artificial Intelligence | 1 | 2024 | 353 | 0.150 |
Why?
| | Tryptophan | 1 | 2021 | 180 | 0.150 |
Why?
| | Quality Assurance, Health Care | 1 | 2021 | 320 | 0.150 |
Why?
| | Urologic Surgical Procedures | 1 | 2021 | 118 | 0.150 |
Why?
| | Metagenomics | 1 | 2021 | 180 | 0.150 |
Why?
| | Diabetes Mellitus | 2 | 2021 | 1083 | 0.150 |
Why?
| | Hospitals | 2 | 2021 | 690 | 0.150 |
Why?
| | Sensitivity and Specificity | 1 | 2024 | 1977 | 0.150 |
Why?
| | Deglutition Disorders | 1 | 2021 | 151 | 0.150 |
Why?
| | Hospitals, Veterans | 1 | 2020 | 255 | 0.150 |
Why?
| | Obesity, Morbid | 1 | 2023 | 277 | 0.150 |
Why?
| | Chronic Disease | 2 | 2022 | 1815 | 0.150 |
Why?
| | Child | 6 | 2023 | 22562 | 0.150 |
Why?
| | Metabolomics | 2 | 2022 | 712 | 0.140 |
Why?
| | Diverticulum | 1 | 2018 | 12 | 0.140 |
Why?
| | Job Satisfaction | 1 | 2021 | 229 | 0.140 |
Why?
| | Hematemesis | 1 | 2018 | 4 | 0.140 |
Why?
| | Symptom Assessment | 2 | 2017 | 132 | 0.140 |
Why?
| | Health Care Costs | 1 | 2021 | 422 | 0.140 |
Why?
| | Fracture Fixation, Internal | 1 | 2020 | 202 | 0.140 |
Why?
| | Range of Motion, Articular | 1 | 2020 | 415 | 0.140 |
Why?
| | Infant | 5 | 2020 | 9908 | 0.140 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2021 | 288 | 0.140 |
Why?
| | Intestines | 1 | 2021 | 355 | 0.140 |
Why?
| | Endoscopic Mucosal Resection | 1 | 2017 | 27 | 0.130 |
Why?
| | Clostridium Infections | 1 | 2018 | 74 | 0.130 |
Why?
| | Fatal Outcome | 1 | 2018 | 311 | 0.130 |
Why?
| | Arthritis, Rheumatoid | 2 | 2016 | 1209 | 0.130 |
Why?
| | Ambulatory Care | 1 | 2021 | 598 | 0.130 |
Why?
| | Quality of Health Care | 1 | 2021 | 649 | 0.130 |
Why?
| | Risk Assessment | 3 | 2016 | 3562 | 0.130 |
Why?
| | Cystadenoma, Mucinous | 1 | 2016 | 10 | 0.120 |
Why?
| | Continuity of Patient Care | 1 | 2019 | 284 | 0.120 |
Why?
| | Budesonide | 1 | 2016 | 56 | 0.120 |
Why?
| | Itraconazole | 1 | 2016 | 9 | 0.120 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2016 | 61 | 0.120 |
Why?
| | Pharmacoepidemiology | 1 | 2015 | 22 | 0.120 |
Why?
| | Endoscopy, Gastrointestinal | 3 | 2023 | 231 | 0.120 |
Why?
| | Pancreatic Diseases | 1 | 2016 | 67 | 0.120 |
Why?
| | Guideline Adherence | 1 | 2020 | 565 | 0.120 |
Why?
| | Neoplasms, Second Primary | 1 | 2016 | 98 | 0.120 |
Why?
| | Cysts | 1 | 2016 | 113 | 0.120 |
Why?
| | Cross-Sectional Studies | 4 | 2025 | 5700 | 0.110 |
Why?
| | Epiphyses | 1 | 2015 | 26 | 0.110 |
Why?
| | Analgesics, Opioid | 1 | 2024 | 1123 | 0.110 |
Why?
| | Hyperlipidemias | 1 | 2016 | 126 | 0.110 |
Why?
| | Data Accuracy | 1 | 2015 | 63 | 0.110 |
Why?
| | Child, Preschool | 5 | 2016 | 11634 | 0.110 |
Why?
| | Antirheumatic Agents | 1 | 2018 | 308 | 0.110 |
Why?
| | Arthritis, Juvenile | 1 | 2015 | 55 | 0.110 |
Why?
| | Polypharmacy | 1 | 2015 | 90 | 0.110 |
Why?
| | Psoriasis | 1 | 2016 | 114 | 0.110 |
Why?
| | Elbow Joint | 1 | 2015 | 75 | 0.110 |
Why?
| | Adolescent | 7 | 2019 | 22326 | 0.110 |
Why?
| | Hedgehog Proteins | 1 | 2016 | 200 | 0.110 |
Why?
| | Neoplasms | 2 | 2023 | 2761 | 0.110 |
Why?
| | Interferon-gamma | 1 | 2017 | 790 | 0.110 |
Why?
| | Prescription Drugs | 1 | 2015 | 112 | 0.110 |
Why?
| | Dilatation | 1 | 2014 | 69 | 0.110 |
Why?
| | Microbiota | 1 | 2022 | 756 | 0.100 |
Why?
| | Cholesterol | 1 | 2016 | 404 | 0.100 |
Why?
| | Burnout, Professional | 1 | 2021 | 461 | 0.100 |
Why?
| | Young Adult | 7 | 2019 | 13878 | 0.100 |
Why?
| | Immunologic Factors | 1 | 2016 | 249 | 0.100 |
Why?
| | Anastomosis, Surgical | 1 | 2014 | 159 | 0.100 |
Why?
| | Streptococcal Infections | 1 | 2016 | 158 | 0.100 |
Why?
| | Virus Diseases | 1 | 2016 | 218 | 0.100 |
Why?
| | Radiation Injuries | 1 | 2014 | 149 | 0.100 |
Why?
| | Foreign Bodies | 1 | 2014 | 108 | 0.100 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2019 | 633 | 0.100 |
Why?
| | Disease Progression | 2 | 2021 | 2831 | 0.100 |
Why?
| | Early Detection of Cancer | 3 | 2022 | 441 | 0.100 |
Why?
| | Reoperation | 1 | 2015 | 600 | 0.090 |
Why?
| | Registries | 1 | 2021 | 2227 | 0.090 |
Why?
| | Primary Health Care | 2 | 2022 | 1768 | 0.090 |
Why?
| | Diabetes Complications | 1 | 2013 | 222 | 0.090 |
Why?
| | Epidemiology | 1 | 2012 | 33 | 0.090 |
Why?
| | Patient Readmission | 1 | 2017 | 703 | 0.090 |
Why?
| | Physical Therapy Modalities | 1 | 2015 | 323 | 0.090 |
Why?
| | Research Support as Topic | 1 | 2012 | 81 | 0.090 |
Why?
| | Tissue and Organ Procurement | 1 | 2015 | 330 | 0.090 |
Why?
| | Endoscopy | 1 | 2014 | 327 | 0.090 |
Why?
| | Biomarkers | 2 | 2020 | 4207 | 0.090 |
Why?
| | Age Distribution | 1 | 2012 | 396 | 0.090 |
Why?
| | Time Factors | 5 | 2021 | 7006 | 0.080 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 2081 | 0.080 |
Why?
| | Physicians | 1 | 2019 | 937 | 0.080 |
Why?
| | Veterans | 1 | 2021 | 1531 | 0.080 |
Why?
| | Medicare | 3 | 2021 | 808 | 0.070 |
Why?
| | Prospective Studies | 4 | 2024 | 7862 | 0.070 |
Why?
| | Drug Prescriptions | 2 | 2024 | 274 | 0.070 |
Why?
| | Laparoscopy | 1 | 2012 | 471 | 0.070 |
Why?
| | Neoplasm Staging | 2 | 2022 | 1404 | 0.060 |
Why?
| | Emergency Service, Hospital | 1 | 2019 | 2251 | 0.060 |
Why?
| | Academic Medical Centers | 2 | 2021 | 531 | 0.060 |
Why?
| | Kaplan-Meier Estimate | 2 | 2020 | 914 | 0.060 |
Why?
| | Pennsylvania | 2 | 2017 | 135 | 0.060 |
Why?
| | Sex Factors | 2 | 2025 | 2074 | 0.060 |
Why?
| | Breast Neoplasms | 1 | 2016 | 2272 | 0.050 |
Why?
| | Survival Analysis | 2 | 2017 | 1328 | 0.050 |
Why?
| | Regression Analysis | 2 | 2017 | 1013 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2017 | 1508 | 0.050 |
Why?
| | Piperidines | 1 | 2024 | 220 | 0.050 |
Why?
| | Insurance Coverage | 1 | 2024 | 240 | 0.050 |
Why?
| | Gastrectomy | 1 | 2023 | 140 | 0.040 |
Why?
| | Replantation | 1 | 2021 | 31 | 0.040 |
Why?
| | Cost Savings | 1 | 2021 | 86 | 0.040 |
Why?
| | Review Literature as Topic | 1 | 2021 | 49 | 0.040 |
Why?
| | Granzymes | 1 | 2021 | 50 | 0.040 |
Why?
| | Documentation | 1 | 2023 | 194 | 0.040 |
Why?
| | Training Support | 1 | 2021 | 36 | 0.040 |
Why?
| | Fingers | 1 | 2021 | 106 | 0.040 |
Why?
| | Salaries and Fringe Benefits | 1 | 2021 | 56 | 0.040 |
Why?
| | Morbidity | 1 | 2021 | 321 | 0.040 |
Why?
| | Hand | 1 | 2021 | 165 | 0.040 |
Why?
| | Metabolic Networks and Pathways | 1 | 2021 | 185 | 0.040 |
Why?
| | Perception | 1 | 2022 | 378 | 0.040 |
Why?
| | SEER Program | 1 | 2020 | 219 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2019 | 3362 | 0.040 |
Why?
| | Dysbiosis | 1 | 2021 | 182 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2021 | 353 | 0.040 |
Why?
| | Medicine | 1 | 2021 | 125 | 0.040 |
Why?
| | Physician's Role | 1 | 2021 | 218 | 0.040 |
Why?
| | Delayed Diagnosis | 1 | 2019 | 91 | 0.040 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2021 | 325 | 0.040 |
Why?
| | Age of Onset | 1 | 2020 | 545 | 0.040 |
Why?
| | Career Choice | 1 | 2021 | 234 | 0.040 |
Why?
| | Pharmacovigilance | 1 | 2018 | 24 | 0.040 |
Why?
| | Mathematical Concepts | 1 | 2018 | 36 | 0.030 |
Why?
| | Margins of Excision | 1 | 2017 | 48 | 0.030 |
Why?
| | Smoking | 1 | 2025 | 1579 | 0.030 |
Why?
| | Decision Support Systems, Clinical | 1 | 2021 | 267 | 0.030 |
Why?
| | Mercaptopurine | 1 | 2016 | 15 | 0.030 |
Why?
| | Prednisone | 1 | 2018 | 231 | 0.030 |
Why?
| | Hip Fractures | 1 | 2018 | 85 | 0.030 |
Why?
| | Etanercept | 1 | 2016 | 61 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2980 | 0.030 |
Why?
| | Pilot Projects | 1 | 2022 | 1829 | 0.030 |
Why?
| | Survival Rate | 1 | 2021 | 1995 | 0.030 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2016 | 57 | 0.030 |
Why?
| | Computational Biology | 1 | 2021 | 673 | 0.030 |
Why?
| | Clinical Competence | 1 | 2024 | 1223 | 0.030 |
Why?
| | Streptococcus pyogenes | 1 | 2016 | 42 | 0.030 |
Why?
| | Decision Making | 1 | 2023 | 957 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2019 | 771 | 0.030 |
Why?
| | Cause of Death | 1 | 2018 | 456 | 0.030 |
Why?
| | Methotrexate | 1 | 2016 | 255 | 0.030 |
Why?
| | Weight Loss | 1 | 2021 | 803 | 0.030 |
Why?
| | Intestinal Mucosa | 1 | 2021 | 654 | 0.030 |
Why?
| | Bias | 1 | 2016 | 208 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2015 | 432 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2016 | 512 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2021 | 1773 | 0.030 |
Why?
| | Mental Recall | 1 | 2015 | 212 | 0.030 |
Why?
| | Computer Simulation | 1 | 2018 | 1018 | 0.030 |
Why?
| | Waiting Lists | 1 | 2015 | 254 | 0.030 |
Why?
| | Medicaid | 1 | 2018 | 457 | 0.030 |
Why?
| | Anticoagulants | 1 | 2018 | 725 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2021 | 2016 | 0.020 |
Why?
| | Respiratory Tract Infections | 1 | 2015 | 389 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2018 | 2103 | 0.010 |
Why?
|
|
Scott's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|